
FDA approves Livsayis, first siRNA therapy for generalized myasthenia gravis with quarterly dosing
The FDA has approved Livsayis (cemdisiran), the first siRNA therapy for adult patients with generalized myasthenia gravis (gMG) who are anti-AChR antibody-positive. Livsayis offers a novel treatment by targeting complement component C5, reducing dise...




